The stock is selling at virtually cash value. ECYT is going to file for a conditional Euro approval shortly based on PFS in the Phase II, and has the Phase III in ovarian cancer already up and running in Europe.
They should be starting a Phase III in ovarian relatively soon with PFS as the primary endpoint in the U.S. And the Phase II in lung cancer should be starting anytime now (Funded by MRK, but run by ECYT.)
They have retained the global rights to the diagnostic EC20.
They have up to $880 million in milestones potentially from the MRK deal. MRK has plans to test EC145 in at least four other cancer indications.
And the EV is at zero????
I bought more today.
Am I missing something here or is this not one of the best bargains in small-cap biotech?
Market Data 
Markets 
AI
